AXSM
Axsome Therapeutics, Inc.
Price Chart
Latest Quote
$251.91
-1.49 (-0.59%)
Current Price
| Previous Close | $253.40 |
| Open | $255.03 |
| Day High | $255.03 |
| Day Low | $248.08 |
| Volume | 598,997 |
Stock Information
| Shares Outstanding | 51.46M |
| Total Debt | $219.90M |
| Cash Equivalents | $305.11M |
| Revenue | $708.24M |
| Net Income | $-188.30M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $12.98B |
| EPS (TTM) | $-3.73 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $12.88B |
| Sales | $708.24M |
| Income | $-188.30M |
| Book/sh | $1.06 |
| Cash/sh | $5.93 |
| Employees | 1K |
Financial Ratios
| Quick Ratio | 1.27 |
| Current Ratio | 1.39 |
| Debt/Eq | 402.84 |
Returns & Margins
| ROA | -16.84% |
| ROE | -349.38% |
| Gross Margin | 92.60% |
| Operating Margin | -32.83% |
| Profit Margin | -26.59% |
Ownership
| Insider Ownership | 15.35% |
| Institutional Ownership | 76.52% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 42.83 |
| P/S | 18.32 |
| P/B | 237.44 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $275.28 |
Technical Indicators
| SMA20 | $238.97 |
| SMA50 | $216.48 |
| SMA200 | $167.49 |
| RSI | 67.73 |
| ATR | 8.9447 |
| Shares Float | 43.56M |
| Short Float | 9.41% |
| Short Ratio | 3.45 |
| Volatility | 0.60 |
| Rel Volume | 0.75 |
Performance History
| Week | +2.36% |
| Month | +10.89% |
| Quarter | +59.73% |
| 6 Months | +72.43% |
| YTD | +41.12% |
| Year | +147.97% |
| 3 Years | +236.93% |
| 5 Years | +273.18% |
| 10 Years | +3986.87% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $252.16 | 506,956 |
| 2026-06-16 | $251.91 | 684,300 |
| 2026-06-15 | $253.40 | 628,300 |
| 2026-06-12 | $255.17 | 441,600 |
| 2026-06-11 | $253.77 | 787,500 |
| 2026-06-10 | $246.34 | 741,200 |
| 2026-06-09 | $245.64 | 918,000 |
| 2026-06-08 | $235.14 | 548,900 |
| 2026-06-05 | $232.32 | 1,118,700 |
| 2026-06-04 | $231.48 | 557,800 |
| 2026-06-03 | $233.49 | 783,800 |
| 2026-06-02 | $222.16 | 603,800 |
| 2026-06-01 | $230.25 | 499,100 |
| 2026-05-29 | $234.48 | 913,900 |
| 2026-05-28 | $232.83 | 472,300 |
| 2026-05-27 | $234.52 | 708,900 |
| 2026-05-26 | $234.20 | 646,600 |
| 2026-05-22 | $235.97 | 674,600 |
| 2026-05-21 | $233.64 | 590,500 |
| 2026-05-20 | $230.62 | 646,800 |
| 2026-05-19 | $226.67 | 510,300 |
| 2026-05-18 | $227.40 | 464,500 |
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
đ° Latest News
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Motley Fool âĸ 2026-06-16T07:50:00Z
Rapport âfully preparedâ to launch seizure drug solo, CEO says
BioPharma Dive âĸ 2026-06-12T09:31:14Z
Axsome Therapeutics Readies Auvelity Alzheimerâs Agitation Launch, Expands CNS Pipeline
MarketBeat âĸ 2026-06-06T04:02:28Z
Does SUNOSI Patent Peace And New Migraine Data Change The Bull Case For Axsome Therapeutics (AXSM)?
Simply Wall St. âĸ 2026-06-05T18:13:05Z
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?
Zacks âĸ 2026-06-05T15:30:24Z
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
Zacks âĸ 2026-06-04T15:30:23Z
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
BioPharma Dive âĸ 2026-06-04T09:22:00Z
Why Is Axsome (AXSM) Down 0.4% Since Last Earnings Report?
Zacks âĸ 2026-06-03T15:30:04Z
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimerâs Agitation Launch
MarketBeat âĸ 2026-05-12T22:08:12Z
Why These Four Biotech Stocks Prove That Follow-On Entries Still Pop Up In Stock Market Leaders
Investor's Business Daily âĸ 2026-05-08T19:45:40Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $44,789,000 | $31,737,000 | $25,606,000 | $4,935,000 |
| Cost Of Revenue | $47,478,000 | $33,303,000 | $26,065,000 | $5,198,000 |
| Total Revenue | $638,496,000 | $385,693,000 | $270,600,000 | $50,037,000 |
| Operating Revenue | $638,496,000 | $385,693,000 | $270,600,000 | $50,037,000 |
| Expenses | ||||
| Interest Expense | $6,557,000 | $6,569,000 | $6,453,000 | $7,335,000 |
| Total Expenses | $807,731,000 | $638,131,000 | $453,507,000 | $226,538,000 |
| Other Income Expense | $-7,912,000 | $-28,124,000 | $-48,918,000 | $-3,298,000 |
| Net Non Operating Interest Income Expense | $-6,557,000 | $-6,569,000 | $-6,453,000 | $-7,335,000 |
| Interest Expense Non Operating | $6,557,000 | $6,569,000 | $6,453,000 | $7,335,000 |
| Operating Expense | $760,253,000 | $604,828,000 | $427,442,000 | $221,340,000 |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-183,174,000 | $-287,216,000 | $-239,238,000 | $-187,134,000 |
| Net Interest Income | $-6,557,000 | $-6,569,000 | $-6,453,000 | $-7,335,000 |
| Normalized Income | $-175,285,736 | $-259,092,000 | $-200,592,780 | $-183,836,000 |
| Net Income From Continuing And Discontinued Operation | $-183,174,000 | $-287,216,000 | $-239,238,000 | $-187,134,000 |
| Total Operating Income As Reported | $-166,762,000 | $-280,562,000 | $-231,825,000 | $-179,799,000 |
| Net Income Common Stockholders | $-183,174,000 | $-287,216,000 | $-239,238,000 | $-187,134,000 |
| Net Income | $-183,174,000 | $-287,216,000 | $-239,238,000 | $-187,134,000 |
| Net Income Including Noncontrolling Interests | $-183,174,000 | $-287,216,000 | $-239,238,000 | $-187,134,000 |
| Net Income Continuous Operations | $-183,174,000 | $-287,216,000 | $-239,238,000 | $-187,134,000 |
| Pretax Income | $-183,704,000 | $-287,131,000 | $-238,278,000 | $-187,134,000 |
| Special Income Charges | $-7,912,000 | $-28,124,000 | $-48,918,000 | $-3,298,000 |
| Operating Income | $-169,235,000 | $-252,438,000 | $-182,907,000 | $-176,501,000 |
| Depreciation Amortization Depletion Income Statement | $6,375,000 | $6,392,000 | $6,375,000 | $4,139,000 |
| Depreciation And Amortization In Income Statement | $6,375,000 | $6,392,000 | $6,375,000 | $4,139,000 |
| Amortization Of Intangibles Income Statement | $6,375,000 | $6,392,000 | $6,375,000 | $4,139,000 |
| Gross Profit | $591,018,000 | $352,390,000 | $244,535,000 | $44,839,000 |
| Per Share | ||||
| Diluted EPS | $-3.68 | $-5.99 | $-5.27 | $-4.60 |
| Basic EPS | $-3.68 | $-5.99 | $-5.27 | $-4.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $-23,736 | $0 | $-10,272,780 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-160,171,000 | $-244,480,000 | $-176,073,000 | $-172,099,000 |
| Total Unusual Items | $-7,912,000 | $-28,124,000 | $-48,918,000 | $-3,298,000 |
| Total Unusual Items Excluding Goodwill | $-7,912,000 | $-28,124,000 | $-48,918,000 | $-3,298,000 |
| Reconciled Depreciation | $9,064,000 | $7,958,000 | $6,834,000 | $4,402,000 |
| EBITDA (Bullshit earnings) | $-168,083,000 | $-272,604,000 | $-224,991,000 | $-175,397,000 |
| EBIT | $-177,147,000 | $-280,562,000 | $-231,825,000 | $-179,799,000 |
| Diluted Average Shares | $49,747,178 | $47,914,253 | $45,425,212 | $40,655,941 |
| Basic Average Shares | $49,747,178 | $47,914,253 | $45,425,212 | $40,655,941 |
| Diluted NI Availto Com Stockholders | $-183,174,000 | $-287,216,000 | $-239,238,000 | $-187,134,000 |
| Tax Provision | $-530,000 | $85,000 | $960,000 | $0 |
| Other Special Charges | $10,385,000 | - | - | - |
| Restructuring And Mergern Acquisition | $-2,473,000 | $28,124,000 | $48,918,000 | $3,298,000 |
| Amortization | $6,375,000 | $6,392,000 | $6,375,000 | $4,139,000 |
| Research And Development | $183,279,000 | $187,077,000 | $97,944,000 | $57,947,000 |
| Selling General And Administration | $570,599,000 | $411,359,000 | $323,123,000 | $159,254,000 |
| Other Taxes | - | - | - | $0 |
| Other Gand A | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $35,734,000 | $-1,921,000 | $125,649,000 | $39,585,000 |
| Total Assets | $689,805,000 | $568,498,000 | $588,236,000 | $331,476,000 |
| Total Non Current Assets | $100,819,000 | $83,434,000 | $83,973,000 | $85,834,000 |
| Other Non Current Assets | $26,838,000 | $18,531,000 | $11,027,000 | $14,721,000 |
| Goodwill And Other Intangible Assets | $52,561,000 | $58,936,000 | $65,328,000 | $69,971,000 |
| Other Intangible Assets | $40,519,000 | $46,894,000 | $53,286,000 | $59,661,000 |
| Current Assets | $588,986,000 | $485,064,000 | $504,263,000 | $245,642,000 |
| Other Current Assets | $13,651,000 | $11,978,000 | $8,115,000 | $2,781,000 |
| Inventory | $27,938,000 | $15,732,000 | $15,135,000 | $4,320,000 |
| Receivables | $224,464,000 | $142,001,000 | $94,820,000 | $37,699,000 |
| Accounts Receivable | $224,464,000 | $142,001,000 | $94,820,000 | $37,699,000 |
| Allowance For Doubtful Accounts Receivable | $-22,210,000 | $-13,504,000 | $-12,500,000 | $-9,097,000 |
| Gross Accounts Receivable | $246,674,000 | $155,505,000 | $107,320,000 | $46,796,000 |
| Cash Cash Equivalents And Short Term Investments | $322,933,000 | $315,353,000 | $386,193,000 | $200,842,000 |
| Cash And Cash Equivalents | $322,933,000 | $315,353,000 | $386,193,000 | $200,842,000 |
| Prepaid Assets | - | - | - | - |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Total Debt | $218,113,000 | $192,955,000 | $186,372,000 | $94,684,000 |
| Long Term Debt And Capital Lease Obligation | $145,134,000 | $189,699,000 | $185,105,000 | $94,259,000 |
| Long Term Debt | $117,746,000 | $180,710,000 | $178,070,000 | $94,259,000 |
| Current Debt And Capital Lease Obligation | $72,979,000 | $3,256,000 | $1,267,000 | $425,000 |
| Current Debt | $70,000,000 | - | - | - |
| Other Current Borrowings | $70,000,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $601,510,000 | $511,483,000 | $397,259,000 | $221,920,000 |
| Total Non Current Liabilities Net Minority Interest | $222,674,000 | $281,379,000 | $258,405,000 | $125,359,000 |
| Other Non Current Liabilities | $77,540,000 | $91,680,000 | $73,300,000 | $31,100,000 |
| Current Liabilities | $378,836,000 | $230,104,000 | $138,854,000 | $96,561,000 |
| Other Current Liabilities | $10,012,000 | $8,285,000 | $6,407,000 | $5,900,000 |
| Payables And Accrued Expenses | $258,907,000 | $190,338,000 | $110,723,000 | $78,952,000 |
| Interest Payable | $43,000 | $1,542,000 | $1,659,000 | $875,000 |
| Payables | $65,638,000 | $72,957,000 | $40,679,000 | $38,605,000 |
| Total Tax Payable | $101,000 | $960,000 | $0 | - |
| Accounts Payable | $65,537,000 | $71,997,000 | $40,679,000 | $38,605,000 |
| Equity | ||||
| Common Stock Equity | $88,295,000 | $57,015,000 | $190,977,000 | $109,556,000 |
| Total Equity Gross Minority Interest | $88,295,000 | $57,015,000 | $190,977,000 | $109,556,000 |
| Stockholders Equity | $88,295,000 | $57,015,000 | $190,977,000 | $109,556,000 |
| Retained Earnings | $-1,305,961,000 | $-1,122,787,000 | $-835,571,000 | $-596,333,000 |
| Other | ||||
| Ordinary Shares Number | $50,882,766 | $48,667,587 | $47,351,363 | $43,498,617 |
| Share Issued | $50,882,766 | $48,667,587 | $47,351,363 | $43,498,617 |
| Tangible Book Value | $35,734,000 | $-1,921,000 | $125,649,000 | $39,585,000 |
| Invested Capital | $276,041,000 | $237,725,000 | $369,047,000 | $203,815,000 |
| Working Capital | $210,150,000 | $254,960,000 | $365,409,000 | $149,081,000 |
| Capital Lease Obligations | $30,367,000 | $12,245,000 | $8,302,000 | $425,000 |
| Total Capitalization | $206,041,000 | $237,725,000 | $369,047,000 | $203,815,000 |
| Additional Paid In Capital | $1,394,251,000 | $1,179,797,000 | $1,026,543,000 | $705,885,000 |
| Capital Stock | $5,000 | $5,000 | $5,000 | $4,000 |
| Common Stock | $5,000 | $5,000 | $5,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $27,388,000 | $8,989,000 | $7,035,000 | $0 |
| Current Capital Lease Obligation | $2,979,000 | $3,256,000 | $1,267,000 | $425,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $36,938,000 | $28,225,000 | $20,457,000 | $11,284,000 |
| Current Accrued Expenses | $193,269,000 | $117,381,000 | $70,044,000 | $40,347,000 |
| Goodwill | $12,042,000 | $12,042,000 | $12,042,000 | $10,310,000 |
| Net PPE | $21,420,000 | $5,967,000 | $7,618,000 | $1,142,000 |
| Gross PPE | $21,420,000 | $5,967,000 | $7,618,000 | $1,142,000 |
| Other Properties | $562,000 | $584,000 | $846,000 | $722,000 |
| Buildings And Improvements | $20,858,000 | $5,383,000 | $6,772,000 | $420,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-93,885,000 | $-128,680,000 | $-145,662,000 | $-117,213,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-93,405,000 | $-128,410,000 | $-145,080,000 | $-116,511,000 |
| Cash Flow From Continuing Operating Activities | $-93,405,000 | $-128,410,000 | $-145,080,000 | $-116,511,000 |
| Operating Gains Losses | $10,385,000 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-480,000 | $-270,000 | $-582,000 | $-702,000 |
| Investing Cash Flow | $-480,000 | $-270,000 | $-582,000 | $-53,702,000 |
| Cash Flow From Continuing Investing Activities | $-480,000 | $-270,000 | $-582,000 | $-53,702,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $67,904,000 | $40,784,000 | $258,750,000 | $243,763,000 |
| Financing Cash Flow | $101,465,000 | $57,840,000 | $331,013,000 | $284,582,000 |
| Cash Flow From Continuing Financing Activities | $101,465,000 | $57,840,000 | $331,013,000 | $284,582,000 |
| Net Other Financing Charges | $-21,885,000 | $-12,634,000 | $-25,156,000 | $-10,432,000 |
| Net Common Stock Issuance | $67,904,000 | $40,784,000 | $258,750,000 | $243,763,000 |
| Common Stock Issuance | $67,904,000 | $40,784,000 | $258,750,000 | $243,763,000 |
| Other | ||||
| Repayment Of Debt | $-334,112,000 | $-990,000 | $0 | $0 |
| Issuance Of Debt | $330,000,000 | $0 | $85,000,000 | $45,000,000 |
| Interest Paid Supplemental Data | $14,626,000 | $19,690,000 | $16,730,000 | $7,686,000 |
| End Cash Position | $322,933,000 | $315,353,000 | $386,193,000 | $200,842,000 |
| Beginning Cash Position | $315,353,000 | $386,193,000 | $200,842,000 | $86,473,000 |
| Changes In Cash | $7,580,000 | $-70,840,000 | $185,351,000 | $114,369,000 |
| Proceeds From Stock Option Exercised | $59,558,000 | $30,680,000 | $12,419,000 | $6,251,000 |
| Net Issuance Payments Of Debt | $-4,112,000 | $-990,000 | $85,000,000 | $45,000,000 |
| Net Long Term Debt Issuance | $-4,112,000 | $-990,000 | $85,000,000 | $45,000,000 |
| Long Term Debt Payments | $-334,112,000 | $-990,000 | $0 | $0 |
| Long Term Debt Issuance | $330,000,000 | $0 | $85,000,000 | $45,000,000 |
| Net PPE Purchase And Sale | $-480,000 | $-270,000 | $-582,000 | $-702,000 |
| Purchase Of PPE | $-480,000 | $-270,000 | $-582,000 | $-702,000 |
| Change In Working Capital | $-22,523,000 | $33,900,000 | $-28,392,000 | $23,670,000 |
| Change In Payables And Accrued Expense | $77,283,000 | $87,383,000 | $38,526,000 | $69,379,000 |
| Change In Accrued Expense | $83,743,000 | $56,065,000 | $36,452,000 | $43,923,000 |
| Change In Payable | $-6,460,000 | $31,318,000 | $2,074,000 | $25,456,000 |
| Change In Account Payable | $-6,460,000 | $31,318,000 | $2,074,000 | $25,456,000 |
| Change In Prepaid Assets | $-1,673,000 | $-3,863,000 | $-5,335,000 | $-2,735,000 |
| Change In Inventory | $-15,670,000 | $-2,439,000 | $-4,462,000 | $-5,275,000 |
| Change In Receivables | $-82,463,000 | $-47,181,000 | $-57,121,000 | $-37,699,000 |
| Changes In Account Receivables | $-82,463,000 | $-47,181,000 | $-57,121,000 | $-37,699,000 |
| Other Non Cash Items | $-909,000 | $31,730,000 | $53,096,000 | $4,825,000 |
| Stock Based Compensation | $93,752,000 | $85,218,000 | $62,620,000 | $37,726,000 |
| Depreciation Amortization Depletion | $9,064,000 | $7,958,000 | $6,834,000 | $4,402,000 |
| Depreciation And Amortization | $9,064,000 | $7,958,000 | $6,834,000 | $4,402,000 |
| Amortization Cash Flow | $6,375,000 | $6,392,000 | $6,375,000 | $4,139,000 |
| Amortization Of Intangibles | $6,375,000 | $6,392,000 | $6,375,000 | $4,139,000 |
| Depreciation | $2,689,000 | $1,566,000 | $459,000 | $263,000 |
| Net Income From Continuing Operations | $-183,174,000 | $-287,216,000 | $-239,238,000 | $-187,134,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-53,000,000 |
| Purchase Of Business | - | $0 | $0 | $-53,000,000 |
| Change In Other Current Assets | - | - | - | - |
Fetched: 2026-06-17